CytomX Therapeutics (Nasdaq: CTMX) will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of U.S. markets. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT, accessible via the Events and Presentations page of its investor relations website, with advance registration recommended.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing masked, conditionally activated PROBODY therapeutics. Its clinical pipeline includes varsetatug masetecan (Varseta-M; CX-2051), a masked ADC targeting EpCAM for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b PROBODY cytokine initially for metastatic melanoma. The company also maintains strategic collaborations with Amgen, Regeneron and Moderna.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The two prior earnings-date announcements were followed by 4.2% and 5.41% 24-hour moves. This schedu...
Analysis
The two prior earnings-date announcements were followed by 4.2% and 5.41% 24-hour moves. This scheduled report provides a comparable catalyst; moderate short positioning and recent CFO net selling remain relevant risk context.
Scheduled full-year and fourth-quarter results before market open with an 8:00 a.m. ET webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The two tag-matched earnings-date announcements were followed by positive 24-hour moves of 4.2% and 5.41%.
Key Terms
antibody-drug conjugates, epcam, topoisomerase-1 inhibitor, tumor microenvironment, +1 more
5 terms
antibody-drug conjugatesmedical
"including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers."
A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.
EpCAM is a protein on the surface of many epithelial cells that is often found at higher levels on certain cancer cells; it helps cells stick together and serves as a visible marker that lab tests and drugs can detect or target. Investors care because diagnostics or therapies that use EpCAM can help identify cancers, deliver treatments directly to tumor cells, or form the basis of clinical trials and partnerships — like a visible flag companies use to find, monitor, or attack tumor cells.
topoisomerase-1 inhibitormedical
"armed with a topoisomerase-1 inhibitor payload"
A topoisomerase-1 inhibitor is a type of drug that blocks an enzyme responsible for untangling DNA so cells can copy and repair it; imagine stopping a person who smooths knots in a rope so the rope can be used. Investors pay attention because these drugs are used to treat cancers and other diseases, so their clinical results, safety profile, regulatory approvals, and patent position directly affect a company’s revenue prospects and stock value.
tumor microenvironmentmedical
"designed to be localized to the tumor microenvironment."
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
t-cell engagersmedical
"including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers."
T-cell engagers are engineered proteins that act like microscopic matchmakers, physically bringing a patient’s immune T cells into close contact with diseased cells so the immune system can recognize and kill them. Investors track them because they represent a promising class of therapies that can drive strong clinical benefits and commercial value if trials succeed, but they also carry development, safety and regulatory risks that can rapidly change a company’s market outlook.
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report second quarter financial results on Thursday, August 6, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc. CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact: Chris Ogden SVP, Chief Financial Officer cogden@cytomx.com
When will CytomX Therapeutics (CTMX) report its Q2 2026 financial results?
CytomX Therapeutics will report its second quarter 2026 financial results on Thursday, August 6, 2026, after U.S. market close. According to CytomX, the release will be followed by a conference call and webcast the same day at 5:00 p.m. ET.
How can investors access the CytomX (CTMX) Q2 2026 earnings conference call?
Investors can access the CytomX Q2 2026 earnings call via a live webcast on the Events and Presentations page of the company’s IR website. According to CytomX, participants should register online at least 10 minutes before the 5:00 p.m. ET start.
Will a replay be available for the CytomX (CTMX) Q2 2026 earnings webcast?
Yes, a replay of the CytomX Q2 2026 earnings webcast will be available. According to CytomX, an archived replay will be posted on the company’s website following the live event, allowing investors to review the discussion after the scheduled call.
What cancer programs are in CytomX Therapeutics’ (CTMX) clinical-stage pipeline?
CytomX’s clinical-stage pipeline includes Varseta-M (CX-2051) for metastatic colorectal cancer and CX-801 for metastatic melanoma. According to CytomX, Varseta-M is a masked EpCAM-targeting ADC, while CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad tumor applicability.
What is Varseta-M (CX-2051) being developed for at CytomX (CTMX)?
Varseta-M (CX-2051) is being developed for the treatment of metastatic colorectal cancer. According to CytomX, it is a masked, conditionally activated antibody-drug conjugate targeting EpCAM, armed with a topoisomerase-1 inhibitor payload, aiming to open a therapeutic window for this antigen.
Which major partners collaborate with CytomX Therapeutics (CTMX) on oncology programs?
CytomX has strategic collaborations with Amgen, Regeneron and Moderna in oncology. According to CytomX, these partnerships support development of its conditionally activated PROBODY therapeutics platform and its broader pipeline of localized biologics for treating various cancers.
